Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2018
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H1 2018
SUMMARY
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 16 molecules. The latest report Galectin 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 9 and 5 respectively. Report covers products from therapy areas Oncology, Respiratory, Cardiovascular, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology, Undisclosed, Immunology, Metabolic Disorders and Musculoskeletal Disorders which include indications Pulmonary Fibrosis, Atopic Dermatitis, Breast Cancer, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Prostate Cancer, Unspecified, Atrial Fibrillation, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Diabetic Nephropathy, Fibrosis, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Pulmonary Arterial Hypertension, Sarcomas and Skin Cancer.
Furthermore, this report also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) pipeline Target constitutes close to 16 molecules. The latest report Galectin 3 - Pipeline Review, H1 2018, outlays comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.
The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 9 and 5 respectively. Report covers products from therapy areas Oncology, Respiratory, Cardiovascular, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology, Undisclosed, Immunology, Metabolic Disorders and Musculoskeletal Disorders which include indications Pulmonary Fibrosis, Atopic Dermatitis, Breast Cancer, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Prostate Cancer, Unspecified, Atrial Fibrillation, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Diabetic Nephropathy, Fibrosis, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Kidney Fibrosis, Liver Cirrhosis, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Portal Hypertension, Pulmonary Arterial Hypertension, Sarcomas and Skin Cancer.
Furthermore, this report also reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
- The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
Galectin Therapeutics Inc
Galecto Biotech AB
GlycoMimetics Inc
iTeos Therapeutics SA
MandalMed Inc
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gal-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gal-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Galectin-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protearin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFD-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board
May 21, 2018: Galecto Biotech Strengthens Executive Team with Appointment of Richard Marshall as Chief Medical Officer
May 14, 2018: Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
Apr 18, 2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Dec 04, 2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals
Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Overview
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development
Galectin Therapeutics Inc
Galecto Biotech AB
GlycoMimetics Inc
iTeos Therapeutics SA
MandalMed Inc
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gal-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gal-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMCT-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Galectin-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protearin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Galectin-3 for Cardiovascular Disease, Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Galectin-1, 3, 9 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFD-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Galectin Therapeutics Announces Richard E. Uihlein Elected Chairman of the Board
May 21, 2018: Galecto Biotech Strengthens Executive Team with Appointment of Richard Marshall as Chief Medical Officer
May 14, 2018: Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
Apr 18, 2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
Apr 04, 2018: Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
Mar 08, 2018: Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
Jan 25, 2018: Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
Dec 14, 2017: Galectin Therapeutics Provides Corporate Update at Annual Meeting
Dec 05, 2017: Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
Dec 04, 2017: Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017
Nov 13, 2017: Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial
Oct 20, 2017: Galectin Therapeutics to Present Clinical Data at The Liver Meeting 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals
Sep 12, 2017: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Galectin Therapeutics Inc, H1 2018
Pipeline by Galecto Biotech AB, H1 2018
Pipeline by GlycoMimetics Inc, H1 2018
Pipeline by iTeos Therapeutics SA, H1 2018
Pipeline by MandalMed Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Galectin Therapeutics Inc, H1 2018
Pipeline by Galecto Biotech AB, H1 2018
Pipeline by GlycoMimetics Inc, H1 2018
Pipeline by iTeos Therapeutics SA, H1 2018
Pipeline by MandalMed Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Galectin Therapeutics Inc
Galecto Biotech AB
GlycoMimetics Inc
iTeos Therapeutics SA
MandalMed Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Galectin Therapeutics Inc
Galecto Biotech AB
GlycoMimetics Inc
iTeos Therapeutics SA
MandalMed Inc
